Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated